HighVista Initiates Position in Cidara with 70,904 Shares Worth $6.79 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: NASDAQ.COM
- New Investment Position: HighVista Strategies initiated a position in Cidara Therapeutics by acquiring 70,904 shares valued at $6.79 million during Q3 2025, representing 1.66% of its 13F reportable assets, indicating a strategic interest in the biotech sector.
- Outstanding Market Performance: As of November 13, 2025, Cidara's shares were priced at $105.99, reflecting a remarkable 662.52% increase over the past year, with a one-year alpha of 675.44 percentage points, showcasing strong market confidence in its future prospects.
- Acquisition News: Cidara recently announced its acquisition by Merck at a price of $221.50 per share, which is expected to keep its stock price elevated in the short term, reflecting market anticipation for its promising influenza prevention drug candidate, CD388.
- Strategic Implications: HighVista's investment comes at a pivotal moment, as Cidara's shareholders stand to benefit from potential drug sales following the Merck acquisition, while HighVista's new stake may yield significant returns in the future.
Analyst Views on CDTX
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
2 Buy
6 Hold
0 Sell
Hold
Current: 220.800
Low
173.00
Averages
209.67
High
221.50
Current: 220.800
Low
173.00
Averages
209.67
High
221.50
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
